

RESEARCH

Open Access

Detecting differentially methylated loci for Illumina Array methylation data based on human ovarian cancer data

Zhongxue Chen^{1*}, Hanwen Huang², Jianzhong Liu³, Hon Keung Tony Ng⁴, Saralees Nadarajah⁵, Xudong Huang⁶, Youping Deng⁷

From The 2011 International Conference on Bioinformatics and Computational Biology (BIOCOMP'11) Las Vegas, NV, USA. 18-21 July 2011

Abstract

Background: It is well known that DNA methylation, as an epigenetic factor, has an important effect on gene expression and disease development. Detecting differentially methylated loci under different conditions, such as cancer types or treatments, is of great interest in current research as it is important in cancer diagnosis and classification. However, inappropriate testing approaches can result in large false positives and/or false negatives. Appropriate and powerful statistical methods are desirable but very limited in the literature.

Results: In this paper, we propose a nonparametric method to detect differentially methylated loci under multiple conditions for Illumina Array Methylation data. We compare the new method with other methods using simulated and real data. Our study shows that the proposed one outperforms other methods considered in this paper.

Conclusions: Due to the unique feature of the Illumina Array Methylation data, commonly used statistical tests will lose power or give misleading results. Therefore, appropriate statistical methods are crucial for this type of data. Powerful statistical approaches remain to be developed.

Availability: R codes are available upon request.

Background

It is well known that DNA methylation has important effects on transcriptional regulation, chromosomal stability, genomic imprinting, and X-inactivation [1,2]. It has been also shown to be associated with many human diseases, such as various types of cancer [3-11].

With the advances of BeadArray technology, genome-wide high-throughput methylation data can be easily generated by Illumina GoldenGate and Infinium Methylation Assays. After preprocessing steps, such as background correction and normalization, are applied to the raw fluorescent intensities, for each locus, from about 30 replicates in the same array a summarized β -value is

generated as follows:
$$\frac{\max\{M, 0\}}{\max\{M, 0\} + \max\{U, 0\} + 100}$$

where M is the average signal from a methylated allele while U is that from unmethylated allele. The β -values are continuous numbers between 0 and 1, with 0 stands for totally unmethylated and 1 for completely methylated.

It has been shown that the β -value is rarely normally distributed [9,12,13]. Therefore the commonly used t-test for case control designs or ANOVA for multiple conditions are not the most powerful approaches when detecting differentially methylated loci. Observing this, Wang has proposed a model-based likelihood ratio test to detect differentially methylated loci for case and control data under the assumption that the β -value follows a three-component normal-uniform distribution [9]. Wang showed that for some situations, their proposed test was better than the simple t-test based on simulation studies.

* Correspondence: zc3@indiana.edu

¹Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, 1025 E. 7th Street, Bloomington, IN 47405, USA

Full list of author information is available at the end of the article

However, in their method, Wang did not consider the effect of age, which has been shown highly associated with methylation [14,15]. Noticing the importance of age effect, one may use a linear regression with age included as a covariate when analyze methylation data with multiple conditions, such as cancer types. However, the underlying assumption of equal variances may not be satisfied [12]. Therefore the commonly used linear regression method may not be appropriate.

In this paper, we consider methylation data with multiple conditions and propose a nonparametric method which incorporates the age effect in a way through the idea of combining p-values from independent tests [12,16,17]. More specifically, we first group subjects into several age groups based on their age; then for each age group, a nonparametric Kruskal-Wallis test is conducted for the given locus and the p-value is recorded. An overall p-value for that locus will be estimated through combining the p-values from all age groups. Using a real methylation data with three conditions and a simulation study, we show that the proposed test is more powerful than other methods, including linear regression.

Method

Proposed method

Assume there are K conditions and G age groups. For each age group g ($g = 1, 2, \dots, G$), we apply the nonparametric Kruskal-Wallis test and obtain a p-value p_g^{KW} , then the overall p-value can be estimated by Fisher test [18]:

$$p_{KW} = \chi_{df=2G}^2(\chi^2 > -2 \sum_{g=1}^G \log(p_g^{KW})) \quad (1)$$

Combined ANOVA test

Similarly, we can use ANOVA to replace KW test for each age group and obtain an overall p-value with p_g^{KW} being replaced by the p-value p_g^{ANOVA} from ANOVA test:

$$p_{ANOVA} = \chi_{df=2G}^2(\chi^2 > -2 \sum_{g=1}^G \log(p_g^{ANOVA})) \quad (2)$$

Combined median test

Another nonparametric test is median test using the following statistic for each age group:

$$M = 4 \sum_{k=1}^K \frac{(A_k - n_k/2)^2}{n_k}, \text{ where } A_k \text{ is the number of}$$

times that the ranks of individual observations from group k which excess the median from the pooled data, and n_k is the sample size of group k . When the sample sizes are large, under the null hypothesis that all samples have the same median, the statistic M has a

chi-square distribution with $K-1$ degrees of freedom. The overall p-value from the combined median test can be calculated:

$$p_{Median} = \chi_{df=2G}^2(\chi^2 > -2 \sum_{g=1}^G \log(p_g^{Median})) \quad (3)$$

Combined welch test

We also consider the nonparametric Welch test. For each age group, we have the test statistic [19]:

$$W = \frac{\sum_{k=1}^K w_k (\bar{x}_k - \hat{\mu})^2 / (K-1)}{1 + [2(K-2)/(K^2-2)] \sum_{k=1}^K h_k},$$

where $w_k = n_k/s_k^2$, $\hat{\mu} = \sum_{k=1}^K w_k \bar{x}_k / w$, $w = \sum_{k=1}^K w_k$, $h_k = (1 - w_k/w^2)/(n_k - 1)$.

Under the null hypothesis, the statistic W is asymptotically distributed as F-distribution with $K-1$ and $f = (K^2 - 1)/(3 \sum_{k=1}^K h_k)$ degrees of freedom. Welch test is an improvement of the Cochran test [20] which usually has inflated type I error rate especially for small sample sizes [19,21]. The overall p-value from the combined Welch test is:

$$p_{Welch} = \chi_{df=2G}^2(\chi^2 > -2 \sum_{g=1}^G \log(p_g^{Welch})) \quad (4)$$

Methods for combining p-values

Besides the Fisher method mentioned above, we also consider Z-test to combine p-values from independent tests. First we calculated the weighted Z statistic using individual p-values from each age group:

$Z = \sum_{g=1}^G n_g \Phi^{-1}(1 - p_g) / \sum_{g=1}^G n_g^2$, where n_g is the total sample size in age group g and Φ is the cumulative distribution function (CDF) of the standard normal distribution. It is easy to see that this statistic has standard normal distribution under the null hypothesis. The overall p-value is calculated by $1 - \Phi(Z)$. Note that here we use one-sided test to obtain the overall p-value.

Simulation settings

To compare each method applied to an individual age group, we simulate β -value for three treatment groups based on beta distribution with parameters a and b , beta (a, b) , and truncated normal distribution on $(0,1)$ with parameters μ, σ^2 , $TN(\mu, \sigma^2)$. We assume the sample sizes (denoted as s in Tables 1, 2 for the simulation results) for the three treatments are either balanced: $s = 30$ for each, or non-balanced: $s = 20, 30$, and 40 . First we compare the

Table 1 Estimated type I error rates at significance level 0.05 with 10000 replicates.

Distribution (sample sizes, parameters)	ANOVA	median	Welch	KW
Beta ($s = 30,30,30, a = 1,1,1, b = 2,2,2$)	0.048	0.040	0.052	0.047
Beta ($s = 30,30,30, a = 1,1,1, b = 10,10,10$)	0.052	0.044	0.053	0.051
Beta ($s = 30,30,30, a = 10,10,10, b = 1,1,1$)	0.047	0.044	0.052	0.048
Beta ($s = 30,30,30, a = 10,10,10, b = 10,10,10$)	0.045	0.045	0.047	0.046
Beta ($s = 20,30,40, a = 1,1,1, b = 2,2,2$)	0.053	0.052	0.050	0.053
Beta ($s = 20,30,40, a = 1,1,1, b = 10,10,10$)	0.049	0.049	0.054	0.048
Beta ($s = 20,30,40, a = 10,10,10, b = 1,1,1$)	0.045	0.049	0.056	0.044
Beta ($s = 20,30,40, a = 10,10,10, b = 10,10,10$)	0.050	0.051	0.043	0.052
TN ($s = 30,30,30, \mu = 0.5,0.5, 0.5, \sigma^2 = 0.1,0.1,0.1$)	0.050	0.044	0.053	0.045
TN ($s = 30,30,30, \mu = 0.5, 0.5, 0.5, \sigma^2 = 0.1,0.2,0.3$)	0.053	0.067	0.047	0.053
TN ($s = 20,30,40, \mu = 0.5, 0.5, 0.5, \sigma^2 = 0.1,0.1,0.1$)	0.050	0.052	0.052	0.049
TN ($s = 20,30,40, \mu = 0.5, 0.5, 0.5, \sigma^2 = 0.1,0.2,0.3$)	0.047	0.054	0.051	0.043

estimated type I error rates with the given significance level of 0.05 under the null hypothesis of no differences among treatment groups. Then we compare the empirical powers from each method under various situations. The empirical power is the proportion of rejected null hypothesis to the number of replicates.

A real data set

We will use a real methylation data set, the United Kingdom Ovarian Cancer Population Study (UKOPS) [15] with 274 controls, 131 pre-treatment cases, and 135 post treatment cases, to compare the performance of the proposed test with others. Those methylation data were generated by the Illumina Infinium Human Methylation27 Bead-Chip and can be downloaded under accession number GSE19711 from the NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>).

For this data set, there are 27578 loci. After data quality control process, we removed some subjects with BS values less than 4000 or the coverage rates less than 95%. We also separate subjects into 6 age groups

(50-55, 55-60, 60-65, 65-70, 70-75, and 75 and over). Table 3 gives the numbers of subjects in each age by treatment groups. For each locus, we perform the above mentioned approaches.

Results

Simulation results

Table 1 reports the estimated type I error rates from each method under different conditions. For most of the time, the estimated type I error rates are close to the nominal significance level as expected. Table 2 gives the empirical powers from each method. It can be seen that the non-parametric method of Mood's median test usually has the lowest powers in the simulations. None of the ANOVA, Welch and KW tests is uniformly most powerful. In words, their performances depend on the distributions from which the data are generated. From our simulation study, the KW test is usually as powerful as or more powerful than the ANOVA test. The true distributions of the β -value may vary from locus to locus; it is impossible to simulate all possible

Table 2 Empirical power at significance level 0.05 with 10000 replicates.

Distribution (sample sizes, parameters)	ANOVA	median	Welch	KW
Beta ($s = 30, 30,30, a = 5,5,5, b = 20,25,30$)	0.821	0.576	0.810	0.775
Beta ($s = 30, 30,30, a = 1.5,2,2.5, b = 20,20,20$)	0.650	0.504	0.648	0.710
Beta ($s = 30, 30,30, a = 20,20,20, b = 1.5,2,2.5,$)	0.658	0.495	0.656	0.713
Beta ($s = 20,30,40, a = 5,5,5, b = 20,25,30$)	0.792	0.546	0.740	0.735
Beta ($s = 20,30,40, a = 1.5,2,2.5, b = 20,20,20$)	0.599	0.479	0.634	0.670
Beta ($s = 20,30,40, a = 20,20,20, b = 1.5,2,2.5$)	0.607	0.475	0.637	0.665
TN ($s = 30, 30,30, \mu = 0.45,0.5,0.55, \sigma^2 = 0.2$)	0.383	0.240	0.378	0.362
TN ($s = 30, 30,30, \mu = 0.45,0.5,0.55, \sigma^2 = 0.1,0.2,0.3$)	0.338	0.325	0.412	0.341
TN ($s = 20,30,40, \mu = 0.45,0.5,0.55, \sigma^2 = 0.2$)	0.349	0.238	0.343	0.328
TN ($s = 20,30,40, \mu = 0.45,0.5,0.55, \sigma^2 = 0.1,0.2,0.3$)	0.219	0.361	0.423	0.259

Table 3 Number of samples in age group by treatment group used in the paper after removing subjects with bs <4000 or coverage rate <95% or age >80.

Age group	control	Pre-treat	Post-treat	Total
50_55	14	15	16	45
55_60	61	17	25	103
60_65	64	17	22	103
65_70	35	17	21	73
70_75	63	24	22	109
75_over	20	18	9	47
Total	257	108	115	480

distributions. However, based on the observation of the real data, we know that the distributions of the β -value are far from the normal distribution, under which ANOVA is the best test. Therefore, we prefer nonparametric tests which are more robust.

Results from real data set


or the real data set, we applied the above mentioned methods to get the overall p-values (either using Fisher or Z test to combine p-values from individual age groups) for each locus. Then we use various cutoff p-values, 0.001, 0.0001, 0.00001, and 0.000001, to count how many loci have smaller p-values for each method. Table 4 reports the results. We can see that the KW method usually finds more significant loci than other methods. It also shows that the two combining p-value methods, Fisher and Z test have similar performances, although Z test usually give a little bit more significant loci expect for the Median test. Figure 1 plots the negative log10 p-values from pairs of the methods. It shows that the KW method gives smaller p-values especially when the differences among the three treatment groups are not large (e.g., the negative log10 p-values between 3 and 6). From Figure 1 we can see that for a given cutoff p-value, most of the loci identified by ANOVA test or Median were also detected by the Welch test; in turn, most of the loci identified by Welch test were also detected by the KW test. This indicates the KW test is more powerful than other methods compared.

Discussion and conclusions

Due to the unique feature of the β -value of methylation data, traditional statistical methods, such as linear regression and ANOVA test may not be appropriate. It has been shown that methylation is highly correlated with age; ignoring age effect may cause many false positives and/or false negatives. The effect of age may also not be linear; therefore we need a better way to account for this effect. In this paper, we use p-value combination method to deal with age effect. For each age group, we use nonparametric method to compare the treatment groups. It is important to find powerful and robust nonparametric methods for this sort of data. Although we found that KW method is more powerful than some other nonparametric methods for methylation data, it is desirable to find more powerful tests in this area. Furthermore, we want to point out that there are many other methods can be used to combine p-values [22,23]; it may also be possible to find a more powerful method to combine p-values for Illumina Array Methylation data. However, based on our experiences, Fisher test is more robust and can be used in situations when a small portion of the p-values are very small; while the Z test is more powerful when the effect sizes are similar (e.g., the p-values don't differ much) for all of the age groups. Finally, although in this paper we use different cutoff p-values to compare the performance of tests, one may want to control the false positive rate. Several multiple comparison methods have been proposed for large scale data set to deal with the situations where the variables (loci) are not independent [24-28]. However, it

Table 4 Number of significant differentially methylated loci detected for given cutoff p-value based on the real data.

Method	1e-3		1e-4		1e-5		1e-6	
	Fisher	Z-test	Fisher	Z-test	Fisher	Z-test	Fisher	Z-test
ANOVA	981	1079	655	690	479	499	350	375
Median	906	893	464	449	255	240	143	127
Welch	1096	1106	640	673	416	424	281	289
K-W	1359	1340	823	859	551	590	381	401



remains to study which approach is more appropriate for the methylation data.

Authors' contributions

ZC devised the basic idea of the new method and drafted the manuscript; HH, JL participated in study design data analysis; HKTN, SN, XH and YD assisted the study and co-wrote the manuscript. All authors read and approve the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This article has been published as part of *BMC Medical Genomics* Volume 6 Supplement 1, 2013: Proceedings of the 2011 International Conference on Bioinformatics and Computational Biology (BIOCOMP'11). The full contents of the supplement are available online at <http://www.biomedcentral.com/bmcmedgenomics/supplements/6/S1>. Publication of this supplement has been supported by the International Society of Intelligent Biological Medicine.

Author details

¹Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, 1025 E. 7th Street, Bloomington, IN 47405,

USA. ²Center for Clinical and Translational Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. ³Chem21 Group, Inc, 1780 Wilson Drive, Lake Forest, IL 60045, USA. ⁴Department of Statistical Science, Southern Methodist University, Dallas, TX 75275, USA. ⁵School of Mathematics, University of Manchester, Manchester, M13 9PL, UK. ⁶Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. ⁷Rush University Cancer Center, Department of Internal Medicine and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.

Published: 23 January 2013

References

1. Kuan PF, Wang S, Zhou X, Chu H: **A statistical framework for Illumina DNA methylation arrays.** *Bioinformatics* 2010, **26**(22):2849.
2. Rakyán VK, Down TA, Thorne NP, Flicek P, Kulesha E, Gräf S, Tomazou EM, Bäckdahl L, Johnson N, Herberth M: **An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs).** *Genome research* 2008, **18**(9):1518-1529.
3. Baylin SB, Ohm JE: **Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction?** *Nature Reviews Cancer* 2006, **6**(2):107-116.
4. Feinberg AP, Tycko B: **The history of cancer epigenetics.** *Nature Reviews Cancer* 2004, **4**(2):143-153.
5. Jabbari K, Bernardi G: **Cytosine methylation and CpG, TpG (CpA) and TpA frequencies.** *Gene* 2004, **333**:143-149.
6. Jones PA, Baylin SB: **The fundamental role of epigenetic events in cancer.** *Nature Reviews Genetics* 2002, **3**(6):415-428.
7. Kulis M, Esteller M: **DNA methylation and cancer.** *Adv Genet* 2010, **70**:27-56.
8. Laird PW: **Principles and challenges of genome-wide DNA methylation analysis.** *Nature Reviews Genetics* 2010, **11**(3):191-203.
9. Wang S: **Method to detect differentially methylated loci with case-control designs using Illumina arrays.** *Genetic Epidemiology* 2011, **35**(December):686-694.
10. Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, Bugge M, Hulten M, Qu X, Russo JJ, Viegas-Péquignot E: **Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene.** *Nature* 1999, **402**(6758):187-191.
11. Hansen KD, Timp W, Bravo HC, Sabuncuyan S, Langmead B, McDonald OG, Wen B, Wu H, Liu Y, Diep D: **Increased methylation variation in epigenetic domains across cancer types.** *Nature Genetics* 2011, **43**(8):768-775.
12. Chen Z, Liu Q, Nadarajah S: **A new statistical approach to detecting differentially methylated loci for case control Illumina array methylation data.** *Bioinformatics* 2012, **28**(8):1109-1113.
13. Huang H, Chen Z: **Age adjusted nonparametric detection of differential DNA methylation with case-control designs.** *Unpublished manuscript* .
14. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, Wiemels JL, Nelson HH, Karagas MR, Padbury JF, Bueno R: **Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context.** *PLoS genetics* 2009, **5**(8):e1000602.
15. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP: **Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer.** *Genome research* 2010, **20**(4):440-446.
16. Chen Z, Ng HKT: **A robust method for testing association in genome-wide association studies.** *Human Heredity* 2012, **73**(1):26-34.
17. Chen Z: **A new association test based on Chi-square partition for case-control GWA studies.** *Genetic Epidemiology* 2011, **35**: 658-658.
18. Fisher RA: **Statistical methods for research workers.** *Edinburgh: Oliver and Boyd* 1932.
19. Welch B: **On the comparison of several mean values: An alternative approach.** *Biometrika* 1951, **38**(3/4):330-336.
20. Cochran WG: **Problems arising in the analysis of a series of similar experiments.** *Journal of Royal Statistical Society, Series C: Applied Statistics* 1937, **4**:102-118.
21. Chen Z, Ng HKT, Nadarajah S: **A note on Cochran test for homogeneity in one-way ANOVA and meta-analysis.** *Statistical Papers* 2012, **1**-10.
22. Chen Z: **Is the weighted z-test the best method for combining probabilities from independent tests?** *Journal of Evolutionary Biology* 2011, **24**(4):926-930.
23. Chen Z, Nadarajah S: **Comments on 'Choosing an optimal method to combine p-values' by Sungho Won, Nathan Morris, Qing Lu and Robert C. Elston.** *Statistics in Medicine* 2009; **28**: 1537-1553. *Statistics in Medicine* 2011, **30**(24):2959-2961.
24. Dudbridge F, Gusnanto A: **Estimation of significance thresholds for genome-wide association scans.** *Genet Epidemiol* 2008, **32**(3):227-234.
25. Gao X, Starmer J, Martin ER: **A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms.** *Genet Epidemiol* 2008, **32**(4):361-369.
26. Moskvina V, Schmidt KM: **On multiple-testing correction in genome-wide association studies.** *Genet Epidemiol* 2008, **32**(6):567-573.
27. Pe'er I, Yelensky R, Altshuler D, Daly MJ: **Estimation of the multiple testing burden for genome-wide association studies of nearly all common variants.** *Genet Epidemiol* 2008, **32**(4):381-385.
28. Chen Z, Liu Q: **A new approach to account for the correlations among single nucleotide polymorphisms in genome-wide association studies.** *Human Heredity* 2011, **72**(1):1-9.

doi:10.1186/1755-8794-6-S1-S9

Cite this article as: Chen et al.: Detecting differentially methylated loci for Illumina Array methylation data based on human ovarian cancer data. *BMC Medical Genomics* 2013 **6**(Suppl 1):S9.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

